IBM shares fell by 2.8% during morning trading after Anderon LLC, a subsidiary of IBM, officially completed the processing of a $1 billion grant under the CHIPS and Science Act with the U.S. Department of Commerce. The funds are intended to accelerate research and development in the production of quantum wafers at the 300-millimeter plant in Albany, New York.
The official announcement did not support the stock prices but triggered profit-taking: the deal had been widely anticipated since May 2026, when a preliminary memorandum of understanding was disclosed, and IBM shares had already surged. An additional negative factor was IBM's weak results for the second quarter of 2026. The company failed to meet analysts' expectations for both revenue and profit, after which management lowered its annual revenue growth forecast. Following this, several law firms initiated investigations into the company.
These unresolved issues are keeping investors from buying amid news that has largely already been priced into the stock. The next scheduled report from IBM is not expected until October 21, 2026 – until then, no significant fundamental catalysts are anticipated. The overall market backdrop today is mixed: the S&P 500 and Nasdaq are showing moderate gains, while the Dow Jones is slightly declining. IBM's decline significantly exceeds that of the Dow, confirming that the pressure on the stock is corporate rather than industry-wide. In light of the consequences of the weak second-quarter report and the lack of new catalysts until October, the shares are trading at $241.40 – significantly below the 52-week high of $332.46.
Related articles
